Autologous stem cell transplantation in multiple myelomy patients <60 vs ≥60 years of age
Date
2003
Authors
Reece, D.
Bredeson, C.
Perez, W.
Jagannath, S.
Zhang, M.
Ballen, K.
Elfenbein, G.
Freytes, C.
Gale, R.
Gertz, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Bone Marrow Transplantation, 2003; 32(12):1135-1143
Statement of Responsibility
DE Reece, C Bredeson, WS Pérez, S Jagannath, MJ Zhang, KK Ballen, GJ Elfenbein, CO Freytes, RP Gale, MA Gertz, J Gibson, SA Giralt, A Keating, RA Kyle, D Maharaj, D Marcellus, PL McCarthy, GA Milone, SD Nimer, S Pavlovsky, LB To, DJ Weisdorf, PH Wiernik, JR Wingard and DH Vesole
Conference Name
Abstract
The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥ the age of 60 (median 63; range 60–73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30–59) years. The two groups were similar except that older patients had a higher ß₂-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4–9) and 1-year treatment-related mortality (TRM) was 9% (6–13) in patients <60 years, compared with 5% (2–10) and 8% (4–14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT >12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2003 Nature Publishing Group